Revisiting the calpain hypothesis of learning and memory 40 years later.

Publication Year: 2024

DOI:
10.3389/fnmol.2024.1337850

PMCID:
PMC10867166

PMID:
38361744

Journal Information

Full Title: Front Mol Neurosci

Abbreviation: Front Mol Neurosci

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Neurosciences

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Conflict of interest MB and XB are co-founders and shareholders of NeurAegis, Inc, a biotech developing selective calpain-2 inhibitors for the treatment of various disorders. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest."

Evidence found in paper:

"The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This research has been supported throughout all these years by grants from NSF, NIH, and more recently by the DoD. XB is supported in part by funds from the Daljit and Elaine Sarkaria Chair."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025